Head-to-head · WeighScore
Embody vs eMed
The verdict
Embody takes it — 76.2/100 to 57.4/100.
Embody grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Embody offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Embody | eMed |
|---|---|---|
| WeighScore | 76.2/100 | 57.4/100 |
| Grade | C | C |
| Scorecard rank | #52 | #399 |
| Semaglutide | $79/mo (all doses, promotional rate, compounded) | Not disclosed |
| Tirzepatide | $129/mo (all doses, promotional rate, compounded) | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #52 · C
Strengths
- Among the lowest flat rates in the compounded segment — $79/mo semaglutide and $129/mo tirzepatide injection at every dose
- Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
- Available in all 50 states with no insurance friction
- 24/7 unlimited clinician messaging and dose-adjustment support included
- Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine
Where it loses points
- The $79 flat rate relies on an auto-applied promo 'locked forever' — list price in the terms is $199/mo and reviewers allege the lock isn't honored
- Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
- Pharmacy partners not publicly named — compounding source transparency is limited
- Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
Graded #399 · C
Strengths
- Prescribes FDA-approved branded GLP-1s (semaglutide and tirzepatide)
- At-home blood collection makes lab work convenient
- Clinician review and ongoing side-effect plus adherence support
- Works with CVS Caremark so eligible employees can buy through benefits
- Established digital health company with national scale
Where it loses points
- Distributed mainly via employers, with limited direct cash-pay access
- No public transparent monthly price for individuals
- Eligibility and subsidy depend on what the employer chooses to cover
- Best suited to workforces, not casual self-pay shoppers
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.